XT-101 harnesses the power of the natural anti-inflammatory protein interluekin- 10 (IL-10) to treat neuro-inflammatory diseases such as neuropathic pain, MS and ALS. In pre-clinical studies in leading animal models of MS, XT-101 has shown the ability to eliminate pain associated with MS, halt disease progression and reverse paralysis caused by the disease.
Xalud Therapeutics, Inc. is an early stage biotechnology company based in San Francisco, CA. Using technologies developed by Dr. Linda Watkins at the University of Colorado Boulder, Xalud is developing novel therapies for the treatment of neuropathic pain and other diseases of the central nervous system. To learn more, please go to www.xaludthera.com .
Peter Heinecke Xaludinfo@xaludthera.com